Videos

“We found that there is going to be a significant proportion of growth in the urology work force related to the number of women in urology, which is really exciting,” says Kate H. Kraft, MD.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for prostate cancer and other PARP agents are moving through the pipeline.

Ellimoottil also discusses the status of his own practice with regards to in-person vs telemedicine visits.

“Speak out. speak out. If you're a physician who's going through a hard time, I can promise you you're not alone,” says Raj S. Pruthi, MD, MHA, FACS.

“I really fell in love with [urology] from the get go,” Kraft says.

“In this study, we show that AI can be used to speed up the time-consuming step of outlining the prostate that's required for targeted prostate biopsy,” says Geoffrey Sonn, MD.

The risk assessment tool helps determine whether a prostate biopsy is necessary when PSA screening is ambiguous.

“In my opinion, burnout has nothing to do with weakness or laziness or incompetence,” says Raj S. Pruthi, MD, MHA, FACS.

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer. 

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

Kretschmer highlights how ongoing research is aiming to optimize use of this noninvasive, urine-based genomic test.

The rationale for utilizing fluoroscopic imaging as well as other evolving technologies that are currently being developed and explored in urology.

Reactions to advances in the quality and safety of newer imaging tests used in prostate cancer.

“Suicide is a disproportionate cause of mortality in physicians,” Pruthi says.

Dr Brad Schwartz comments on his satisfaction with current imaging systems used in urology and the impact of image quality on treatment decisions and clinical outcomes.

Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT. 

The ExoDx Prostate test helps physicians determine whether a prostate biopsy is necessary when PSA screening is ambiguous.

Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection. 

Brad Schwartz, DO, FACS, comments on radiation exposure associated with imaging assessments used in urology and explains what he and colleagues are doing to minimize exposure and address patient concerns.

On overview of the current types of imaging assessments available to diagnose and manage patients with a urological disease.

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

In terms of physician burnout, “The pandemic has only made a bad situation worse,” says Raj S. Pruthi, MD, MHA, FACS.

Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection. 

Frontline immune checkpoint inhibitor therapy may improve overall survival in this setting.

Around the Practice: Metastatic Castrate Resistant Prostate Cancer

Around the Practice: High-Risk Renal Cell Carcinoma

Loeb and Stork offer pointers for beginners and current users alike.

“I think one of the issues that we face as physicians…is during training, long hours and a lack of control over our schedule indoctrinates surgeons with habits that may be counterproductive to achieving life balance after entering practice,” says Raj S. Pruthi, MD, MHA FACS.

Galsky highlights final OS data from the IMvigor130 trial, along with an exploratory analysis examining outcomes by type of chemotherapy used.